Date: 2015-04-27
Type of information: Product acquisition
Compound: Balmex®
Company: Moberg Pharma (Sweden) Chattem (USA - TN), a Sanofi company (France)
Therapeutic area: Dermatological diseases - Inflammatory diseases
Type agreement: product acquisition
Action mechanism:
Disease: diaper rash
Details: * On April 27, 2015, Moberg Pharma has acquired Balmex®, a well-established Over-The-Counter brand in the U.S. from Chattem, Inc, the U.S. Consumer Healthcare Division of Sanofi. Net sales of the brand is trending on an annual rate exceeding $4 million. Balmex® is an established and trusted brand among parents with products used for diaper rash, primarily in babies. An adult line for soothing skin irritations was launched in 2013. The brand will be sold through Moberg’s current OTC channel in the U.S, primarily in chain drugstores, such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart as well as specialty retailers including Toys R’ Us and buybuyBABY. The transaction was completed April 24th, 2015.
Financial terms: The purchase price is $3.9 million and financed by available cash resources.
Latest news:
